Simponi under the microscope: new registry tracks Long-Term risks in ulcerative colitis patients

NCT ID NCT02808780

Ongoing Knowledge-focused Sponsor: Janssen Biotech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 4 times

Summary

This registry follows 535 adults with moderate-to-severe ulcerative colitis who are taking or starting Simponi. Researchers will track serious side effects like infections, cancers, and pregnancy outcomes over time. The goal is to better understand the long-term safety of this medication in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Simponi (golimumab)
What this could lead to: If successful, this registry will provide a clearer picture of Simponi's long-term safety, helping doctors and patients make more informed treatment decisions.
What could go wrong: This is an observational registry, not a treatment trial, so it won't test new therapies. Results may not apply to all patients, and rare side effects might still be missed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma neoplasm ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS

Contacts and locations

Locations

Study site

Murrieta, California, United States
Study site

Rialto, California, United States
Study site

Ventura, California, United States
Study site

Coral Gables, Florida, United States
Study site

Fort Myers, Florida, United States
Study site

Lake Worth, Florida, United States
Study site

Lauderdale Lakes, Florida, United States
Study site

Miami, Florida, United States
Study site

Tampa, Florida, United States
Study site

Suwanee, Georgia, United States
Study site

Chicago, Illinois, United States
Study site

Sylvania, Ohio, United States
Study site

Pittsburgh, Pennsylvania, United States
Study site

Houston, Texas, United States
Study site

San Antonio, Texas, United States
Study site

Lansdowne Town Center, Virginia, United States
Study site

Salzburg, Austria
Study site

Sankt Poelten Noe, Austria
Study site

Vienna, Austria
Study site

New Westminster, British Columbia, Canada
Study site

Vancouver, British Columbia, Canada
Study site

Oshawa, Ontario, Canada
Study site

Ottawa, Ontario, Canada
Study site

Pilsen, Czechia
Study site

Clermont-Ferrand, France
Study site

Clichy, France
Study site

Créteil, France
Study site

Grenoble, France
Study site

Montpellier, France
Study site

Nice, France
Study site

Pierre-Bénite, France
Study site

Saint-Priest-en-Jarez, France
Study site

Strasbourg, France
Study site

Berlin, Germany
Study site

Dessau Roblau, Germany
Study site

Halle, Germany
Study site

Hamburg, Germany
Study site

Heidelberg, Germany
Study site

Kiel, Germany
Study site

Leipzig, Germany
Study site

Ludwigshafen, Germany
Study site

Lyneburg, Germany
Study site

München, Germany
Study site

Saarbrücken, Germany
Study site

Athens, Greece
Study site

Heraklion, Greece
Study site

Ioannina, Greece
Study site

Thessaloniki, Greece
Study site

Busan, South Korea
Study site

Gyeonggi-do, South Korea
Study site

Seongnam-si, South Korea
Study site

Seoul, South Korea
Study site

A Coruña, Spain
Study site

Barcelona, Spain
Study site

Córdoba, Spain
Study site

Fuenlabrada, Spain
Study site

Huelva, Spain
Study site

Madrid, Spain
Study site

Majadahonda, Spain
Study site

San Sebastián de los Reyes, Spain
Study site

Valencia, Spain
Study site

Vigo, Spain
Study site

Zaragoza, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.